Product Name: Flt4 (1065-1071) pY1068
Product Number: PE-04AMK99
Size: | 200 µg | | Price: | 47.00 |
| 1 mg | | $US | 94.00 |
| 5 mg | | | 206.00 |
Peptide Name: Flt4 (1065-1071) pY1068
Product Use: Services as a blocking peptide for use with the VEGFR3-pY1068 rabbit polyclonal antibody (Cat. No.: AB-PK853) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y1068 phosphorylation is predicted to be stimulatory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DPD-pY-VRK
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1145.2 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Flt4 - pY1068 phosphosite-specific antibody (Cat. No.: AB-PK853) Scientific Background: VEGFR3 (Flt4) is a protein-tyrosine kinase of the TK group and VEGFR family. It is a receptor for vascular endothelial growth factors (VEGF) C and D that is essential in angiogenesis and vasculogenesis. It is activated by binding VEGF-C and VEGF-D, which induce dimerization and autophosphorylation. VEGFR3 plays critical roles in some lymphangiogenetic mechanisms in cancer and metastasis. It is expressed in acute myeloid leukemia and other types of cancer, and are related to tumour angiogenesis and efficacy of traditional therapies.